Dennis Ding
Stock Analyst at Jefferies
(0.10)
# 4,109
Out of 4,711 analysts
11
Total ratings
12.5%
Success rate
-21.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $3.20 | +150.00% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $15.21 | +130.11% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $9.80 | +83.67% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.21 | +118.07% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $6.03 | -0.50% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.18 | +177.78% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $18 | $0.42 | +4,159.35% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $51.40 | -57.20% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $25.50 | -5.88% | 1 | Dec 19, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | $10 | $11.57 | -13.57% | 1 | Oct 26, 2021 |
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $3.20
Upside: +150.00%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $15.21
Upside: +130.11%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $9.80
Upside: +83.67%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.21
Upside: +118.07%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $6.03
Upside: -0.50%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.18
Upside: +177.78%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $18
Current: $0.42
Upside: +4,159.35%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $51.40
Upside: -57.20%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $25.50
Upside: -5.88%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.57
Upside: -13.57%